NCT04982913View on ClinicalTrials.gov

Single Dose and Multiple Dose Safety, Tolerability, PK，and Food Effect Study，and Interaction With Oseltamivir Study of HEC116094 in Healthy Adult Subjects

PHASE1CompletedINTERVENTIONAL

Enrollment

118

Participants

Timeline

Start Date

August 24, 2021

Primary Completion Date

October 2, 2022

Study Completion Date

October 2, 2022

Conditions

Influenza

Interventions

DRUG

HEC116094

Part B：Mulltiple doses up to 5 days； Part C：Each cycle was administered for 5 days

Trial Locations (1)

Unknown

The Shanghai xuhui district central hospital, Shanghai

All Listed Sponsors

lead

Sunshine Lake Pharma Co., Ltd.

INDUSTRY

NCT04982913 - Single Dose and Multiple Dose Safety, Tolerability, PK，and Food Effect Study，and Interaction With Oseltamivir Study of HEC116094 in Healthy Adult Subjects | Biotech Hunter | Biotech Hunter